Overview Durvalumab Long-Term Safety and Efficacy Study Status: Recruiting Trial end date: 2022-10-31 Target enrollment: Participant gender: Summary The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information. Phase: Phase 4 Details Lead Sponsor: AstraZenecaCollaborators: CISCRPIqvia Pty LtdMedidata SolutionsParexelTreatments: Antibodies, MonoclonalDurvalumab